Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Regency Therapeutics division of Luitpold Pharmaceuticals has launched SPRIX (Kétorolac Trométhamine), the US Food and Drug Administration approved systemic non-opioid nasal spray, in the US.
Subscribe to our email newsletter
SPRIX, which uses an Aptar Pharma nasal spray pump, is a non-invasive treatment for pain management.
Aptar Pharma worked closely with Roxro Pharma for over 7 years to develop the perfect nasal delivery system for SPRIX.
Luitpold Pharmaceuticals, a New York based US subsidiary of Daiichi Sankyo Co, has acquired Roxro Pharma in December 2010.
The Aptar Pharma nasal device allows ketorolac tromethamine (a potent NSAID) to be delivered intranasally to adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level.